InnovAge Holding Corp (INNV)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ
Market Cap: $1.29B
Last updated: Nov 17, 2026 at 11:05 AM ET
InnovAge Holding Corp (INNV) Earnings: Report Dates and Results
InnovAge Holding (INNV) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, InnovAge Holding reported EPS of $0.14, above the $0.11 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INNV has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.0% below the $0.10 reported for the quarter ended Dec 31, 2025.
INNV Earnings Call
The latest INNV earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 27 quarters below that had an estimate, INNV beat 12, missed 14 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $264.76M, up 12.1% from $236.10M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.14 | $0.11 | N/A | +27.27% | Beat | +100.0% | 1 | 0 up, 0 down | Nov 3, 2026 | $264.76M |
| Jun 30, 2026 | $0.06 | $0.09 | $0.09 - $0.09 | -33.33% | Miss | N/A | 1 | 1 up, 0 down | Sep 8, 2026 | $261.95M |
| Mar 31, 2026 | $0.17 | $0.05 | $0.05 - $0.05 | +240.00% | Beat | +750.0% | 1 | 0 up, 0 down | May 5, 2026 | $251.94M |
| Dec 31, 2025 | $0.10 | $0.04 | $0.04 - $0.04 | +150.00% | Beat | N/A | 1 | 0 up, 0 down | Feb 3, 2026 | $239.71M |
| Sep 30, 2025 | $0.07 | $0.04 | $0.04 - $0.04 | +75.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 4, 2025 | $236.10M |
| Jun 30, 2025 | -$0.01 | -$0.01 | N/A | +24.81% | Beat | N/A | 1 | 0 up, 0 down | Sep 9, 2025 | $221.42M |
| Mar 31, 2025 | $0.02 | -$0.01 | N/A | +300.00% | Beat | N/A | 1 | 0 up, 0 down | May 6, 2025 | $218.14M |
| Dec 31, 2024 | -$0.01 | -$0.01 | N/A | +13.04% | Beat | -200.0% | N/A | 0 up, 0 down | Feb 4, 2025 | $209.00M |
| Sep 30, 2024 | -$0.02 | -$0.01 | N/A | -100.00% | Miss | N/A | 4 | 0 up, 0 down | Nov 5, 2024 | $205.14M |
| Jun 30, 2024 | -$0.01 | -$0.03 | -$0.04 - -$0.01 | +66.67% | Beat | N/A | 3 | 0 up, 0 down | Sep 10, 2024 | $199.40M |
| Mar 31, 2024 | -$0.04 | -$0.03 | -$0.04 - -$0.03 | -33.33% | Miss | N/A | 4 | 0 up, 0 down | May 7, 2024 | $193.07M |
| Dec 31, 2023 | $0.01 | -$0.02 | -$0.05 - -$0.02 | +150.00% | Beat | N/A | 4 | 0 up, 0 down | Feb 6, 2024 | $188.90M |
| Sep 30, 2023 | -$0.08 | -$0.04 | -$0.05 - -$0.02 | -100.00% | Miss | N/A | 4 | 0 up, 0 down | Nov 7, 2023 | $182.49M |
| Jun 30, 2023 | -$0.09 | -$0.04 | -$0.06 - -$0.02 | -125.00% | Miss | N/A | 4 | 0 up, 0 down | Sep 12, 2023 | $176.87M |
| Mar 31, 2023 | -$0.05 | -$0.05 | -$0.07 - -$0.03 | 0.00% | In line | N/A | 4 | 0 up, 0 down | May 9, 2023 | $172.54M |
| Dec 31, 2022 | -$0.07 | -$0.09 | -$0.13 - -$0.07 | +22.22% | Beat | -275.0% | 4 | 0 up, 0 down | Feb 7, 2023 | $167.46M |
| Sep 30, 2022 | -$0.05 | -$0.04 | -$0.05 - -$0.01 | -25.00% | Miss | -171.4% | 4 | 0 up, 0 down | Nov 8, 2022 | $171.22M |
| Jun 30, 2022 | -$0.09 | -$0.03 | -$0.03 - -$0.02 | -200.00% | Miss | -280.0% | 5 | 0 up, 0 down | Sep 13, 2022 | $172.86M |
| Mar 31, 2022 | -$0.01 | $0.06 | -$0.02 - $0.06 | -116.67% | Miss | -114.3% | 5 | 0 up, 0 down | May 10, 2022 | $177.36M |
| Dec 31, 2021 | $0.04 | $0.07 | N/A | -42.86% | Miss | N/A | 7 | 0 up, 0 down | Feb 9, 2022 | $175.35M |
| Sep 30, 2021 | $0.07 | $0.05 | $0.04 - $0.05 | +40.00% | Beat | -6.0% | 6 | N/A | Nov 9, 2021 | $173.07M |
| Jun 30, 2021 | $0.05 | $0.06 | $0.05 - $0.08 | -16.67% | Miss | N/A | 5 | 0 up, 0 down | Sep 21, 2021 | $171.62M |
| Mar 31, 2021 | $0.07 | -$0.07 | N/A | +200.00% | Beat | +1.0% | 4 | N/A | May 10, 2021 | $156.31M |
| Dec 31, 2020 | -$0.37 | N/A | N/A | N/A | N/A | -633.9% | N/A | N/A | Mar 5, 2021 | $157.31M |
| Sep 30, 2020 | $0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | $152.57M |
| Jun 30, 2020 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | $152.49M |
| Mar 31, 2020 | $0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | N/A |
| Dec 31, 2019 | $0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | $144.77M |
| Sep 30, 2019 | -$0.81 | -$0.40 | -$0.53 - -$0.28 | -102.50% | Miss | N/A | 2 | N/A | Nov 14, 2019 | $5.75M |
| Jun 30, 2019 | -$0.66 | -$0.30 | -$0.42 - -$0.19 | -120.00% | Miss | N/A | 2 | N/A | Aug 13, 2019 | $6.85M |
| Mar 31, 2019 | -$0.81 | -$0.54 | -$0.54 - -$0.54 | -50.00% | Miss | N/A | 1 | N/A | May 15, 2019 | $5.36M |
| Dec 31, 2018 | -$0.81 | -$0.54 | N/A | -50.00% | Miss | N/A | N/A | N/A | Mar 22, 2019 | $4.75M |
| Sep 30, 2018 | -$1.20 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2018 | $7.38M |
| Jun 30, 2018 | -$0.94 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2018 | $7.31M |
| Mar 31, 2018 | -$1.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2018 | $4.54M |
| Dec 31, 2017 | -$1.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 8, 2018 | $2.38M |
| Sep 30, 2017 | -$0.86 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 | $2.22M |
| Jun 30, 2017 | -$0.74 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2017 | $2.04M |
| Mar 31, 2017 | -$1.98 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 12, 2017 | $2.18M |
| Dec 31, 2016 | -$3.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 6, 2017 | $1.69M |
Annual EPS
EPS for the fiscal year ended Jun 30, 2026 was $0.40, a profit after a loss of $0.02 per share the year before. It was -$10.17 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Jun 30, 2026 | $0.40 | N/A |
| Jun 30, 2025 | -$0.02 | N/A |
| Jun 30, 2024 | -$0.12 | N/A |
| Jun 30, 2023 | -$0.26 | -2700.0% |
| Jun 30, 2022 | $0.01 | N/A |
| Jun 30, 2021 | -$0.18 | N/A |
| Jun 30, 2020 | -$0.83 | N/A |
| Jun 30, 2019 | -$3.48 | N/A |
| Jun 30, 2018 | -$3.86 | N/A |
| Jun 30, 2017 | -$10.17 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,200 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,180 | 7 | |
| 2026Q2 | Jun 30, 2026 | 5,340 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,853 | 7 | |
| 2025Q4 | Dec 31, 2025 | 6,080 | 8 | |
| 2025Q3 | Sep 30, 2025 | 6,264 | 9 | |
| 2025Q2 | Jun 30, 2025 | 6,979 | 8 | |
| 2025Q1 | Mar 31, 2025 | 6,193 | 8 | |
| 2024Q4 | Dec 31, 2024 | 5,023 | 7 |
2026Q3 Earnings Call
Opening remarks
Ryan Kubota Head of Investor Relations Thank you, operator. Good afternoon, and thank you all for joining the InnovAge 2026 Fiscal Third Quarter Earnings Call. With me today is Patrick Blair, CEO; and Ben Adams, CFO. Today, after the market closed, we issued an earnings press release containing detailed information on our fiscal third quarter results. You may access the release on the Investor Relations section of our company website, innovage.com. For those listening to the rebroadcast of this call, we remind you that the remarks made herein are as of today, Tuesday, May 5, 2026, and have not been updated subsequent to this call. During our call, we will refer to certain non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures can be found in our earnings press release posted on our website. We will also make statements that are considered forward-looking, including those related to our 2026 fiscal year projections and guidance, future growth prospects and growth strategy, our clinical and operational value initiatives, the effects of recent legislation and federal budget cuts, including Medicare and Medicaid rate pressures, seasonality of cost trends, the status of current and future legal proceedings and regulatory actions and other expectations. Listeners are cautioned that all of our forward-looking statements involve certain assumptions that are inherently subject to risks and uncertainties that can cause our actual results to differ materially from our current expectations. We advise listeners to review the risk factors and other discussions included in our annual report on Form 10-K for fiscal year 2025 and any subsequent reports filed with the SEC, including our most recent quarterly report on Form 10-Q. After the completion of our prepared remarks, we will open the call for questions. I will now turn the call over to our CEO, Patrick Blair. Patrick?
Patrick Blair Chief Executive Officer Thank you, Ryan, and good afternoon, everyone. I'd like to begin by thanking our InnovAge colleagues, our participants and their families, our government partners and our investor community for your continued trust and support. The work our teams do every day to care for a very complex and vulnerable population is what drives our performance, and I'm proud of the progress we're making and the consistency we're beginning to demonstrate as an organization. We delivered a solid third quarter and continue to see steady momentum across the business. These results reflect stronger operating execution and the benefits of the investments we've made over the past few years to strengthen the platform. For the quarter, we reported approximately $252 million in total revenue, center-level contribution margin of $61 million and adjusted EBITDA of $30 million. We ended the quarter serving approximately 8,050 participants in 6 states across 20 centers.
Frequently Asked Questions About INNV
When is InnovAge Holding's next earnings date?
InnovAge Holding's next earnings report is expected for Feb 1, 2027.
Did INNV beat earnings estimates last quarter?
Yes. InnovAge Holding reported EPS of $0.14 for the quarter ended Sep 30, 2026, above the $0.11 estimate, a 27.27% surprise.
What EPS do analysts expect from INNV next quarter?
The consensus EPS estimate for InnovAge Holding for the quarter ending Dec 31, 2026 is $0.09 from 1 analyst, with estimates from $0.09 to $0.09.
How often does INNV beat earnings estimates?
InnovAge Holding beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +99.60%.
INNV pages: Overview, Earnings, Forecast, Financials, Valuation